Stock Markets February 19, 2026

Johnson & Johnson Moves Toward Sale of DePuy Synthes, Potential Price Tag Exceeds $20 Billion

Financial packages being prepared as private equity groups and rival device makers weigh bids for the hip and knee implant business

By Sofia Navarro JNJ
Johnson & Johnson Moves Toward Sale of DePuy Synthes, Potential Price Tag Exceeds $20 Billion
JNJ

Johnson & Johnson is preparing to market its orthopedics unit, DePuy Synthes, assembling documents and financial information ahead of meetings with potential buyers in the coming weeks. The business, which posted $9.3 billion in sales last year, could command a valuation above $20 billion and is drawing interest from private equity consortia as well as competing medical device firms.

Key Points

  • Johnson & Johnson is assembling documents and financial information for DePuy Synthes ahead of buyer meetings scheduled in the coming weeks.
  • DePuy Synthes generated $9.3 billion in sales last year and could be valued at more than $20 billion.
  • Potential buyers include consortia of large private equity firms and competing medical device companies, indicating interest from both financial and strategic acquirers.

Johnson & Johnson has begun actively preparing DePuy Synthes for a potential sale, according to people familiar with the plans. The company is compiling offering materials and financial data for the orthopedics unit before holding discussions with prospective buyers over the next few weeks.

DePuy Synthes, J&J's business that manufactures devices used in hip and knee replacement procedures, reported $9.3 billion in sales in the last year. Sources indicate the unit could be valued at more than $20 billion if taken to market.

Interest appears to be emerging from multiple quarters. Several large private equity firms are said to be weighing the formation of acquisition teams to bid on the business. In addition, the unit may attract suitors from within the medical device industry itself, as competing companies evaluate whether to pursue an acquisition.

Johnson & Johnson had earlier signaled intentions to separate the orthopedics unit from its broader operations. Instead of a separation, the company is now exploring the option of an outright sale, a shift that is reflected in the preparation of detailed financial documentation ahead of buyer meetings.

The company is expected to meet with potential buyers in the coming weeks, after which any formal process - such as launch of a sale or solicitation of bids - would depend on interest and further internal decisions. At this stage, the information available is limited to the preparations and the reported areas of buyer interest.

Market participants will likely watch for how private equity groups and strategic medical device companies respond. The combination of DePuy Synthes' recent revenue run rate and reported potential valuation places it among sizable healthcare asset transactions, although the ultimate structure and timing of any deal remain to be determined.


Market implications

  • Healthcare and medical device sectors could see transactional activity if a sale is launched.
  • Private equity firms focused on healthcare assets are among the most directly impacted buyers.
  • Any significant divestiture may influence competitive dynamics in orthopedics equipment and implant markets.

Risks

  • It is unclear whether Johnson & Johnson will proceed with a sale after the upcoming meetings; the company is only reported to be exploring an outright sale option rather than having committed to one.
  • The ultimate buyer group and transaction structure are uncertain - while private equity firms and medical device companies are reported as interested, no formal bids or deal terms have been disclosed.
  • The reported potential valuation is an estimate; the article provides no confirmation of an agreed price or that the valuation will be met in a sale.

More from Stock Markets

WarrenAI Ranks Five Solar Stocks Poised for Diverse Risk-Reward Profiles in 2026 Feb 20, 2026 U.S. Equities Close Higher as Consumer Services, Tech and Telecoms Lead Gains Feb 20, 2026 Electra Battery Materials Upsizes ATM to $25M; Shares Slip After Hours Feb 20, 2026 Mexican equities close higher as industrial and consumer sectors lead gains Feb 20, 2026 Toronto Market Hits Record as Materials and Tech Drive Gains Feb 20, 2026